CONSORT Diagram.

<p>CONSORT Diagram.</p

Efficacy results.

<p>Efficacy results.</p

Adverse events of grade 3 or 4.

<p>Adverse events of grade 3 or 4.</p

Patient and disease characteristics at baseline.

<p>Patient and disease characteristics at baseline.</p

PFS* (A) and OS* (B) distribution according to the 4 classes of metabolic response.

<p>Class 1: no metabolic unresponsive lesion; Class 2: minority of unresponsive lesion among whole body target tumour load; Class 3: majority of whole body target tumour load does not respond; Class 4: all target lesions are non-responding, or, presence of progressive lesions [progression defined as >25% increase of FDG uptake on second PET, or appearance of a new lesion]. *from date of the second FDG PET-CT.</p

Classes of metabolic responses.

<p>Class 1: no metabolic unresponsive lesion; Class 2: minority of unresponsive lesion among whole body target tumour load; Class 3: majority of whole body target tumour load does not respond; Class 4: all target lesions are non-responding, or, presence of progressive lesions [progression defined as >25% increase of FDG uptake on second PET, or appearance of a new lesion].</p

Consort Diagram.

<p>Consort Diagram.</p

PFS and OS distribution according to the dichotomized mR classifications.

<p>PFS and OS distribution according to the dichotomized mR classifications.</p

Most important (>10%) side effects in the 88 patients who received treatment according to Common Toxicity Criteria CTC3.0.

<p><b>Uncommon side effects</b>: gastrointestinal perforations (<i>N</i> = 2), acute pancreatitis (N = 1), digestive haemorrhages (<i>N</i> = 2), septic shock (<i>N</i> = 1), thromboembolic events (<i>N</i> = 2), and hiccups (<i>N</i> = 2)</p><p>Most important (>10%) side effects in the 88 patients who received treatment according to Common Toxicity Criteria CTC3.0.</p